Neurotoxicity and carcinogenicity of N-methylolacrylamide in F344 rats and B6C3F1 mice.

Toxicology and carcinogenicity studies of N-methylolacrylamide were conducted by administering the chemical by gavage in water to both sexes of F344/N rats and B6C3F1 mice 5 times per week for 16 d, 13 wk, or 2 yr. In 16-d studies, rats receiving doses of 200 mg/kg or higher and mice receiving 400 mg/kg died. In 13-wk studies, all rats given 100 mg/kg or higher doses died. Rats receiving 50 mg/kg or higher doses developed hindlimb ataxia progressing to paralysis. In neurobehavioral assessments, decreased forelimb and hindlimb grip strength occurred in rats at doses as low as 12.5 mg/kg. Landing footspread was also increased in dosed rats compared to controls. Axon filament and myelin sheath degeneration in the spinal cord and/or peripheral nerves occurred in rats receiving doses of 25 mg/kg or higher. Necrosis in the granular cell layer of the cerebellum was seen in rats given 200 mg/kg. Mice receiving 200 mg/kg in 13-wk studies died. Decreased grip strength was noted in mice at doses as low as 25 mg/kg, and rotarod performance was also affected by N-methylolacrylamide administration, but no neuropathology was seen microscopically. Testicular weights were decreased at doses as low as 12.5 mg/kg, and hepatocellular necrosis, thymic lymphocyte necrosis, and hemorrhage, necrosis, and mineralization of the zona reticularis of the adrenal gland were seen in mice that died (200 mg/kg). In 2-yr studies, survival and weight gains in male and female rats receiving doses of 6 or 12 mg/kg/d were minimally affected. No biologically important clinical signs or neoplastic or nonneoplastic lesions were attributed to N-methylolacrylamide administration to rats, suggesting that higher doses could have been tolerated. In mice, survival was not different between dosed and control groups (0, 25, or 50 mg/kg/d). Body weights were higher by as much as 25% in dosed compared to control groups. No compound-related clinical signs were observed, but increases in neoplasms of the harderian gland, liver, and lung were clearly related to chemical administration in both sexes of mice. Benign granulosa-cell neoplasms of the ovary were also increased in dosed female mice.

[1]  J. Haseman,et al.  Influence of viral infections on body weight, survival, and tumor prevalence of B6C3F1 (C57BL/6N x C3H/HeN) mice in carcinogenicity studies. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[2]  R. Tennant,et al.  Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP. , 1988, Mutation research.

[3]  R. Maronpot,et al.  Ovarian toxicity and carcinogenicity in eight recent National Toxicology Program studies. , 1987, Environmental health perspectives.

[4]  K. Morgan,et al.  Ovarian neoplasms in F344 rats and B6C3F1 mice. , 1987, Environmental health perspectives.

[5]  J. Haseman,et al.  Influence of body weight on the incidence of spontaneous tumors in rats and mice of long-term studies. , 1987, The American journal of clinical nutrition.

[6]  G A Boorman,et al.  Liver lesions in B6C3F1 mice: the National Toxicology Program, experience and position. , 1987, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement.

[7]  Keith A. Johnson,et al.  Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. , 1986, Toxicology and applied pharmacology.

[8]  R. Kodell,et al.  Primary harderian gland neoplasms in mice. , 1983, Journal of the National Cancer Institute.

[9]  E. Mcconnell Pathology Requirements for Two-year Rodent Studies II. Alternative Approaches , 1983, Toxicologic pathology.

[10]  E. Mcconnell Pathology Requirements for Rodent Two-Year Studies I. A Review of Current Procedures , 1983, Toxicologic pathology.

[11]  A. Clark,et al.  Choline Deficiency, Partial Hepatectomy, and Liver Tumors in Rats and Mice , 1982, Toxicologic pathology.

[12]  R. Maronpot,et al.  Interpretation of Rodent Hepatocellular Proliferative Alterations and Hepatocellular Tumors in Chemical Safety Assessment1, 2 , 1982, Toxicologic pathology.

[13]  Tilson Ha The neurotoxicity of acrylamide: an overview. , 1981 .

[14]  R. Tarone,et al.  Tests for trend in life table analysis , 1975 .

[15]  P. Edwards,et al.  The distribution and metabolism of acrylamide and its neurotoxic analogues in rats. , 1975, Biochemical pharmacology.

[16]  P. M. Edwards The Neurotoxicity and Conversion of N -Hydroxymethylacrylamide in vivo , 1974 .

[17]  D. Cox Regression Models and Life-Tables , 1972 .

[18]  K. Hashimoto,et al.  Biochemical studies on acrylamide, a neurotoxic agent. , 1970, Biochemical pharmacology.

[19]  C. Dunnett A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .

[20]  H. Feuer,et al.  The Synthesis and Reactions of Unsaturated N-Methylolamides1,2,3 , 1953 .